Publications by authors named "R De Haan"
Development and Validation of the Satisfaction Concerning Stoma Care Questionnaire (SSCQ).
J Wound Ostomy Continence Nurs
September 2024
Purpose: The purpose of this research was to develop the Satisfaction Concerning Stoma Care Questionnaire (SSCQ) and evaluate its structural and convergent validity and internal reliability.
Design: Instrument development and evaluation of validity and reliability.
Subjects And Setting: A preliminary 22-item SSCQ was administered in a larger web-based survey to members of 2 ostomy-related patient associations with members throughout the Netherlands.
Background: Cognitive reserve is a potential mechanism to cope with brain damage as a result of dementia, which can be defined by indirect proxies, including education level, leisure time activities, and occupational attainment. In this study we explored the association between dementia diagnosis and type of occupation in a retrospective Dutch outpatient memory clinic sample of patients with primary progressive aphasia (PPA), behavioral variant frontotemporal dementia (bvFTD), and Alzheimer's Dementia (AD).
Methods: We included data from 427 patients (bvFTD = 87, PPA = 148, AD = 192) and compared the frequency of occupations (11 categories) between patients and data from the Dutch census using Pearson tests and we calculated odds ratios (OR) by means of multinomial logistic regression analyses.
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.
Cochrane Database Syst Rev
February 2024
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) causes progressive or relapsing weakness and numbness of the limbs, which lasts for at least two months. Uncontrolled studies have suggested that intravenous immunoglobulin (IVIg) could help to reduce symptoms. This is an update of a review first published in 2002 and last updated in 2013.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the impact of small vessel disease (SVD) in predicting Alzheimer's disease outcomes in non-demented individuals.
- About 39% of participants showed no signs of either SVD or amyloid beta (Aβ), while those with Aβ exhibited quicker cognitive decline.
- Though SVD alone slightly indicated increased dementia risk in participants without Aβ, it did not worsen cognitive decline in those with Aβ.
Purpose: PARP-inhibitors have potent radiosensitizing properties in pre-clinical models. To identify the maximum tolerated dose (MTD) of the PARP-inhibitor Olaparib in combination with radiotherapy in patients with head and neck cancer, a single institutional phase-I dose escalation trial was initiated.
Patients And Methods: The starting dose of Olaparib was 25 mg BID, combined with radiotherapy (70 Gy in 35 fractions).